PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Becton, Dickinson and Company

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BD Biosciences Announces Winners of Research Grant Program - Seven Scientists Receive Immunology Research Grants
BD Biosciences Announces Winners of Research Grant Program


NewswireToday - /newswire/ - San Jose, CA, United States, 2010/12/16 - Seven Scientists Receive Immunology Research Grants. NYSE: BDX

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today the latest round of winners of its Research Grant Program.

“By awarding grants to these promising scientists, BD Biosciences continues to support innovative biomedical research across the United States,” said William Rhodes, President, BD Biosciences. “We see this as a way to help assure future discovery and innovation despite difficult economic challenges.”

An independent panel of distinguished scientists selected the winners. The grant recipients will each receive a $10,000 grant of research reagents to help carry out their research.

The BD Biosciences Research Grant Program winners for the fall 2010 cycle are:

• Arnold Chin, M.D., Ph.D., Assistant Professor of Urology at the University of California, Los Angeles Johnson Comprehensive Cancer Center. Dr. Chin uses animal and human studies to understand the role of inflammation and immune activation in bladder cancer. In addition, he hopes to develop a personalized therapy program for bladder cancer patients by correlating molecular signatures to susceptibility of individual patient tumor cells to standard and novel treatments. Dr. Chin’s abstract is titled, “Immune and Molecular Profiling in Bladder Cancer for Personalized Therapy.”

• Arlene Dent, M.D., Ph.D., Assistant Professor of Pediatrics at Case Western Reserve University. Dr. Dent’s research involves methods of detecting rare, antigen-specific memory B cells using flow cytometry and quantum dots. Her goal is to understand better the differences and similarities between vaccine- and infection-induced immunity in children. Dr. Dent’s abstract is titled, “A Novel Assay to Detect Antigen-Specific Memory B Cells.”

• Asifa Zaidi, Ph.D., Instructor, Division of Clinical Immunology, Johns Hopkins University School of Medicine. Dr. Zaidi studies the contribution of basophils, a class of immune system cell, in pathogenesis of asthma in an experimental animal model. Ultimately, she aims to uncover basophil-based mechanisms amenable to drug intervention to prevent acute asthma episodes. Dr. Zaidi’s abstract is titled, “Basophils and Murine Experimental Model of Asthma.”

• Veronica Martinez-Cerdeno, Ph.D., Assistant Professor, Department of Pathology and Laboratory Medicine, University of California, Davis. Dr. Martinez-Cerdeno investigates a potential etiology of autism spectrum disorders during pregnancy. Specifically, she will inject human maternal antibodies into the brains of mice and follow brain pathology using immunohistochemistry and behavioral testing. Dr. Martinez-Cerdeno’s abstract is titled, “Antibodies Present in the Plasma of Women with Autistic Progeny Alter the Neurogenic Divisions of Precursor Cells in the Prenatal Mouse Cerebral Cortex, and the Social Behavior of Adult Mice.”

• Edward Diaz, M.D., Resident Physician at the Glickman Urologic and Kidney Institute at the Cleveland Clinic. By studying the role of mTOR signaling within urothelial carcinoma cancer stem cells, Dr. Diaz hopes to gain further insight into mTOR’s function in bladder cancer. He plans to study the mTOR cascade by isolating stem cells from tumor specimens, propagating a cancer cell line in vitro, and studying the expression of mTOR using various staining methods. Dr. Diaz’s abstract is titled, “Urothelial Cancer Stem Cells and mTOR Signaling.”

• Elena Galkina, Ph.D., Assistant Professor at Eastern Virginia Medical School. Dr. Galkina’s research focuses on the role of the immune response in the etiology of type 2 diabetes, particularly on the effects of immune-related inflammation in the islets. She plans to use multi-color flow cytometry to quantify the immune compositions of non-diabetic and type 2 diabetic islets. This project also aims to characterize the immune response to possible mediators of type 2 diabetes in human islets. Dr. Galkina’s abstract is titled, “Type 2 Diabetes and Islet Immune Response.”

• Kristen Hoek, Ph.D., Research Fellow at the Vanderbilt University Medical Center. Dr. Hoek’s research interests involve the migration of B cells in autoimmune disease. Her objectives are to identify and control B cell defects in autoimmune disorders such as type 1 diabetes in ways that alleviate symptoms without immunocompromising subjects. The molecular target for these investigations is Kruppel-like factor 2, a transcription factor that regulates B cell migration. Dr. Hoek’s abstract is titled, “B Cell Trafficking in Mucosal Immunology and Autoimmune Disease.”

Additional information about the BD Biosciences Research Grant Program is available at

About the BD Biosciences Research Grant Program
The BD Biosciences Research Grant Program aims to reward and enable important research by providing vital funding for scientists pursuing innovative experiments to advance the scientific understanding of disease. The grant submissions are judged by a distinguished research panel of non-affiliated scientists. Through its grant program, BD Biosciences supports innovation in research and development as well as helps enable the next generation of scientific breakthroughs.

About BD
BD ( is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.

[Content made possible by PRZOOM indexing services]

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Becton, Dickinson and Company


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

BD Biosciences Announces Winners of Research Grant Program

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

BD |
Publisher Contact: Jeff Ezell - 
201-847-5533 jeff_ezell[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Becton, Dickinson and Company securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Becton, Dickinson and Company / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  MagLar, Inc.

Visit  Deb Sheppard - Medium Psychic Author Speaker

  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (